Navigation Links
SENOMYX ANNOUNCES CORPORATE UPDATE AND FIRST QUARTER FINANCIAL RESULTS
Date:4/25/2013

development, as well as our ability to identify proteins primarily involved in the perception of salt taste in humans. Risks that contribute to the uncertain nature of the forward-looking statements include: Senomyx has no experience in manufacturing, marketing, or selling flavor ingredients on a commercial scale and may not successfully implement its direct sales strategy; Senomyx is dependent on its product discovery and development collaborators for all of Senomyx's development revenues; Senomyx is currently dependent on its current and any future product discovery and development collaborators to develop, manufacture, and commercialize any flavor ingredients Senomyx may discover; Senomyx may not be able to establish new collaborations or other business arrangements and/or maintain existing collaborations on acceptable terms;  large companies are typically conservative when implementing changes to their branded products, and may not begin or expand their use of Senomyx flavor ingredients when expected or at all; development activities for newer flavor ingredients, including S617, may not demonstrate an acceptable safety profile or meet other commercialization criteria; Senomyx or its collaborators may be unable to obtain and maintain the regulatory approval required for flavor ingredients to be incorporated into products that are sold; even if Senomyx or its collaborators receive a regulatory approval and incorporate Senomyx flavor ingredients into products, those products may never be commercially successful; Senomyx flavor ingredients may not be useful or cost-effective for formulation into products; Senomyx or its collaborators may be unable to manufacture Senomyx flavor ingredients at commercial scale; Senomyx's ability to compete in the flavor ingredients market may decline if Senomyx does not adequately protect its proprietary technologies; and Senomyx's discovery and development programs may not be successful or result in the discovery of new flavor i
'/>"/>
SOURCE Senomyx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Senomyx To Webcast Corporate Presentation At The 25th Annual ROTH Conference
2. Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
3. SENOMYX AND FIRMENICH ANNOUNCE AMENDMENT OF THEIR SWEET TASTE PROGRAM AGREEMENT
4. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE 12TH ANNUAL NEEDHAM HEALTHCARE CONFERENCE
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
6. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
7. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
8. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
9. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
10. WuXi PharmaTech Announces Third-Quarter 2011 Results
11. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  Technology Applications International ... that its wholly-owned subsidiary Renuell Int,l, Inc. has signed ... and Space Administration ("NASA") at the Johnson Space Center ... See photos: tapplic.com/houstonphotos/ ... are very pleased to announce our latest, exclusive agreement ...
(Date:9/2/2014)... September 02, 2014 Opertech Bio, ... highly efficient, cost effective approach to sensory evaluation, ... 8,820,265 by the U.S. Patent and Trademark Office, ... , “Opertech’s taste evaluation technology called ... automated high throughput system for rapid characterization of ...
(Date:9/2/2014)... 2, 2014  Xencor, Inc. (NASDAQ: ... monoclonal antibodies for the treatment of autoimmune diseases, ... the appointment of Debra Zack , M.D., ... of Lloyd Rowland , senior vice president, ... "Debra,s expertise in biologics clinical development and ...
(Date:9/2/2014)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... targeting specific pathogens that cause serious infections and ... preclinical toxicology study of SYN-004. Per U.S. Food ... was required to move the Company,s lead anti-infective, ... effects of Clostridium difficile (C. difficile), ...
Breaking Biology Technology:Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5
... Micromet, Inc. (Nasdaq: ... for the treatment of cancer, inflammation and autoimmune diseases, ... Itin, will present at the Cowen Health Care Conference ... on Tuesday, March 17, 2009. A simultaneous webcast ...
... Company Receives Allowance of Patent Claims in the ... Highlighted in Nature Biotechnology -BRITISH COLUMBIA, Canada, March ... IXSBF; TSX VENTURE: IXS; http://www.ixsbio.com ), a ... monoclonal antibodies based on its Dynamic Cross Linking ...
... Wis., March 6 Mach One Corporation (Pink ... subsidiary, Modular Process Constructors LLC, is changing its ... vision, and announces that it received a contract ... consumer health company. The contract is for a ...
Cached Biology Technology:Micromet to Present at the Cowen Health Care Conference on March 17, 2009 2Micromet to Present at the Cowen Health Care Conference on March 17, 2009 3Micromet to Present at the Cowen Health Care Conference on March 17, 2009 4InNexus Biotechnology Announces New Patents Protecting Novel Cell Penetrating DXL(TM) Antibodies 2InNexus Biotechnology Announces New Patents Protecting Novel Cell Penetrating DXL(TM) Antibodies 3Mach One Subsidiary Modular Process Constructors LLC Changes Name to MPS BioPharm to Better Reflect its Vision 2
(Date:9/2/2014)... with the participation of the University of Granada has ... place in the Iberian Peninsula around the mid Holocene ... dust coming from the Sahara increased. The data came ... Alpine lake in Sierra Nevada (Granada) , This study, ... based on the sedimentation of atmospheric dust from the ...
(Date:9/2/2014)... ideal source of nutrition for infants and it ... evolution and civilizations of human beings. Unlike our ... of bacterial species, including some opportunistic pathogens of ... scientists and physicians. , Indeed, the existence of ... of co-evolutionary and co-adaptive interactions between the microbiome ...
(Date:9/2/2014)... 2014 A study published in the September ... American Academy of Child and Adolescent Psychiatry ... psychiatric diagnosis had an increased risk of developing ... Using data from the nationwide Danish registers, a ... Nielsen, Psychiatry, Aalborg University Hospital, Denmark, studied 48,299children ...
Breaking Biology News(10 mins):Scientists obtain new data on the weather 10,000 years ago from sediments of a lake in Sierra Nevada 2Are human breast milk microbiome 'neutral'? 2Are human breast milk microbiome 'neutral'? 3Risk of diabetes in children and adolescents exposed to antipsychotics 2
... for many people with depression and anxiety disorders, and ... care providers, according to researchers who analyzed the results ... shown to have tremendous benefits for mental health," says ... Program at Southern Methodist University in Dallas. "The more ...
... at Ume University and the Sahlgrenska Academy at the University ... can be found in fish that have been swimming in ... found in higher concentrations in the blood of fish than ... this hormone can lead to infertility in fish. The ...
... neurodegenerative disease spinocerebellar ataxia type 5 (SCA5) damages nerve ... report that the defective protein responsible for the disease ... inside neurons. The study appears in the April 5 ... ( www.jcb.org ). SCA5 results from a faulty ...
Cached Biology News:Mental health providers should prescribe exercise more often for depression, anxiety 2Medicine residues may threaten fish reproduction 2Defective protein is a double hit for ataxia 2
... QRT-PCR Mixes are formulated for use in ... SYBR Green. One-step QRT-PCR mixes offer a ... The pipetting steps are minimised, making the ... ,The 2x ABsolute QRT-PCR Mix is supplied ...
... of environmental and pathophysiological stressful conditions trigger ... known as heat shock proteins (HSPs), more ... The Hsp90 family of proteins in ... beta, Grp94, and Trap-1 (Hsp75). It was ...
... bespoke, cost-effective solutions for complex protein processing and production ... experience to help you develop a solution to your ... , do ... transfer all methodology to your own ...
... The Schleicher & Schuell BioScience Arraying ... dedicated to custom protein and nucleic ... project teams, comprised of R&D, Engineering, ... closely with collaborators every step of ...
Biology Products: